ID   LC5
AC   CVCL_5G52
DR   BioSample; SAMN06481116
DR   Wikidata; Q54902173
RX   Patent=US5582967;
RX   PubMed=2201317;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Group: Patented cell line.
CC   Problematic cell line: Contaminated. Parent cell line (L-132) has been shown to be a HeLa derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00515.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-842.
CC   Population: African American.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
DI   NCIt; C27677; Human papillomavirus-related endocervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1908 ! L-132
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 10-04-25; Version: 17
CH   CVCL_5G53 ! LC5-HIV
//
RX   Patent=US5582967;
RA   Erfle, Volker
RA   Mellert, Werner
RT   "Human cell line LC5 and its use.";
RL   Patent number US5582967, 10-Dec-1996.
//
RX   PubMed=2201317; DOI=10.1097/00002030-199006000-00006;
RA   Mellert, Werner
RA   Kleinschmidt, Andrea
RA   Schmidt, Jorg
RA   Festl, Herbert
RA   Emler, Stefan
RA   Roth, Willy Kurt
RA   Erfle, Volker
RT   "Infection of human fibroblasts and osteoblast-like cells with
RT   HIV-1.";
RL   AIDS 4:527-535(1990).
//